Journal of Cancer Therapy
Vol.6 No.15(2015), Paper ID 61883, 10
pages
DOI:10.4236/jct.2015.615132
Phase II Study of Carboplatin and Pemetrexed Followed by Gefitinib for Patients with Advanced Non-Small Cell Lung Cancer Harboring Sensitive EGFR Mutation
Saki Manabe, Fumihiro Oshita, Shuji Murakami, Tetsuro Kondo, Haruhiro Saito, Takeshi Kaneko, Kouzo Yamada
Department of Thoracic Oncology, Kanagawa Cancer Center, Yokohama, Japan
Department of Thoracic Oncology, Kanagawa Cancer Center, Yokohama, Japan
Department of Thoracic Oncology, Kanagawa Cancer Center, Yokohama, Japan
Department of Thoracic Oncology, Kanagawa Cancer Center, Yokohama, Japan
Department of Thoracic Oncology, Kanagawa Cancer Center, Yokohama, Japan
Department of Pulmonology, Yokohama City University Graduate School of Medicine, Yokohama, Japan
Department of Thoracic Oncology, Kanagawa Cancer Center, Yokohama, Japan
Department of General Medicine, Kanagawa Prefectural Ashigarakami-Hospital, Matsuda, Japan
Copyright © 2015 Saki Manabe, Fumihiro Oshita, Shuji Murakami, Tetsuro Kondo, Haruhiro Saito, Takeshi Kaneko, Kouzo Yamada et al. This is
an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any
medium, provided the original work is properly cited.
How to Cite this Article
Manabe, S. , Oshita, F. , Murakami, S. , Kondo, T. , Saito, H. , Kaneko, T. and Yamada, K. (2015) Phase II Study of Carboplatin and Pemetrexed Followed by Gefitinib for Patients with Advanced Non-Small Cell Lung Cancer Harboring Sensitive EGFR Mutation.
Journal of Cancer Therapy,
6, 1214-1222. doi:
10.4236/jct.2015.615132.